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osting by EAbstract The present study deals with the development of transferosomal gel containing insulin by
reverse phase evaporation method for painless insulin delivery for use in the treatment of insulin
dependent diabetes mellitus. The effect of independent process variables like ratio of lipids (soya
lecithin:cholesterol), ratio of lipids and surfactants, and ratio of surfactants (Tween 80:sodium
deoxycholate) on the in vitro permeation ﬂux (lg/cm2/h) of formulated transferosomal gels contain-
ing insulin through porcine ear skin was optimized using 23 factorial design. The optimal perme-
ation ﬂux was achieved as 13.50 ± 0.22 lg/cm2/h with drug entrapment efﬁciency of 56.55 ±
0.37% and average vesicle diameter range, 625–815 nm. The in vitro insulin permeation through
porcine ear skin from these transferosomal gel followed zero-order kinetics (R2 = 0.9232–0.9989)
over a period of 24 h with case-II transport mechanism. The in vitro skin permeation of insulin from
optimized transferosomal gel by iontophoretic inﬂuence (with 0.5 mA/cm2 current supply) also
provided further enhancement of permeation ﬂux to 17.60 ± 0.03 lg/cm2/h. The in vivo study of
optimized transferosomal gel in alloxan-induced diabetic rat has demonstrated prolonged hypogly-
cemic effect in diabetic rats over 24 h after transdermal administration.
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lsevier1. Introduction
Delivery of therapeutically active proteins and peptides has
found an important position in therapeutics. Currently, most
of the commercially available therapeutic proteins and peptides
are administered parenterally, because oral administration of
these candidates is limited due to their rapid hydrolytic and
enzymatic degradations (Marschutz and Bernkop-Schnurch,
2000; Nayak, 2010). Among various therapeutically active pro-
teins and peptides, insulin is widely used clinically for the treat-
ment of insulin dependent diabetes mellitus (IDDM) or type-I
diabetes (Tripathi, 1999). Insulin is a peptide hormone
356 J. Malakar et al.composed of 51 amino acid residues and has molecular weight
about 5.7 kDa (Davis, 2005). The molecular structure of insulin
composed of 2 peptide chains: A chain (21 amino acid residues)
and B chain (30 amino acid residues) (Malakar et al., 2011).
Although parenteral insulin is commercially available and gen-
erally used, but this is associated with some serious adverse
effects like peripheral hyperinsulinemia, smooth muscles cell
proliferation and a diabetic micro- and macro-angiopathy
(Khafagy et al., 2007). In addition, the burden of daily injec-
tions, physiological stress, pain, inconvenience, cost, and the
localized deposition of insulin leads to a local hypertrophy
and fat deposition in the injection sites. To limit these draw-
backs, transdermal route for insulin delivery as an alternative
non-parenteral route of administration can be used to treat
diabetic patients. During the past few years, various experimen-
tal methodologies have been successfully developed for facili-
tating transdermal delivery of insulin (Sen et al., 2002; Pillai
et al., 2003; Amnon and Wormser, 2007; Cevc, 2003; King
et al., 2002).
Recently, the vesicular drug-carrier system, transferosome
have been reported to enhance the transdermal delivery of
drugs, when applied onto the skin non-occlusively (Benson,
2006; Patel et al., 2009). Transferosomes are artiﬁcial vesicles,
being several orders of magnitude more deformable than stan-
dard liposomes (Cevc and Blume, 2003; Jain et al., 2003). The
deformability of liposomes for improved skin permeation of
drug molecules can be achieved by using surfactants in appro-
priate ratio (Maghraby et al., 1999). Transferosomes have the
ability to overcome the permeation difﬁculty by squeezing
themselves along the inter-cellular sealing lipid of the stratum
corneum (Pandey et al., 2009). The resulting ﬂexibility of
transferosomes membranes minimizes the risk of complete ves-
icle rupture in the skin and allows transferosomes to follow the
natural water gradient across the epidermis, after application
onto the skin (Fig. 1).
Pharmaceutical scientists often face the challenge of ﬁnding
the appropriate combination of variables that will produce the
product with optimum properties (Nayak and Pal, 2011). The
optimization technique encompasses designing a set of experi-
ment that will reliably measure the response variables, ﬁtting a
mathematical model to the data, conducting appropriateFigure 1 Schematic diagram describing interastatistical test to assure that the best possible model is chosen,
and determining the optimum value of independent variables
that produce best response (Schwartz et al., 2007). In the pres-
ent investigation, we attempted to develop and optimize trans-
ferosomal gel containing insulin for improved transdermal
permeation using 23 factorial design. We also have studied
the transdermal permeation of the optimized transferosomal
gel by iontophoresis for further insulin permeation improve-
ment. Finally, we have performed a short-term in vivo evalua-
tion of optimized transferosomal gel containing insulin on
alloxan-induced diabetic rats.
2. Experimental
2.1. Materials
Human insulin (Torrent Pharmaceutical Ltd., India), soya lec-
ithin (L-a-phosphatidyl choline, Himedia Laboratories Pvt.
Ltd., India), cholesterol (C24H46O; M.W. 386.67, purity
P99%, Merck Specialties Pvt. Ltd., India), sodium deoxycho-
late (C24H39O4Na; M.W.414.56, Loba Chemie Pvt. Ltd.,
India), Tween 80 (Merck Specialties Pvt. Ltd., India), dimethyl
sulfoxide (Merck Specialties Pvt. Ltd., India) and diethyl ether
(Merck Specialties Pvt. Ltd., India) were used. Demineralized
and double distilled water was used. All chemicals and re-
agents used were of analytical grade.
2.2. Preparation of transferosomes
Transferosomes were formulated by reverse phase evaporation
method with some modiﬁcations as described in the literature
(Yang et al., 2002). At ﬁrst, soya lecithin and cholesterol were
taken in a cleaned beaker as lipids. Then, Tween 80 as surfac-
tant was poured in the same beaker and dissolved in a solvent
mixture of diethyl ether and chloroform (3:1). The beaker was
kept at the room temperature for 24 h until the thin ﬁlm
formed. Insulin solution (1.40 mg/ml in water) was poured
onto the thin ﬁlm and sonicated by a probe sonicator (FS-
600. Frontline Electronics and Machinery Pvt. Ltd., India) at
a frequency of 20 KhZ for 2 min. After that, the ﬁlm was
hydrated using edge deactivator, sodium deoxycholate inction of the transferosome with skin tissue.
Table 1 Composition of different coded values in 23 full factorial design.
Coded values Independent variables (actual values)
Ratio of lipids (soya
lecithin:cholesterol) (X1)
Ratio of lipids and
surfactants (X2)
Ratio of surfactant (Tween
80:Na deoxycholate) (X3)
Levels Low (1) 8:3 1:1 4:6
High (+1) 10:1 1.47:1 7:3
Table 2 23 full factorial design (coded values in bracket) with response; [(+1) = High level, (1) = Low level].
Formulation codes Factors Response
Ratio of lipids
(soyalecithin:cholesterol) (X1)
Ratio of lipids and
surfactants (X2)
Ratio of surfactant
(Tween 80:Na deoxycholate) (X3)
Flux, J (lg/cm2/h)
(Mean ± SE, n= 3)
F 1 (+1) (+1) (+1) 12.72 ± 0.21
F 2 (+1) (+1) (1) 9.72 ± 0.20
F 3 (+1) (1) (+1) 8.52 ± 0.12
F 4 (1) (+1) (+1) 14.38 ± 0.23
F 5 (+1) (1) (1) 11.13 ± 0.20
F 6 (1) (+1) (1) 13.39 ± 0.26
F 7 (1) (1) (+1) 6.39 ± 0.11
F 8 (1) (1) (1) 11.50 ± 0.24
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2 min to obtain transferosomal suspensions. In each suspen-
sions, 2% v/v dimethyl sulfoxide (DMSO) was added as chem-
ical permeation enhancer. Then various formulated
transferosomal suspensions were passed through Whatman
ﬁlter paper (No. 40). Then, these transferosomal suspensions
were transferred to 5% w/v methylcellulose gel and stored in
cool and dark place.
2.3. Experimental design
A three-factor, two-level factorial design (23) were employed
for optimization procedure with ratio of lipids (soya
lecithin:cholesterol) (X1), ratio of lipids and surfactants (X2),
and ratio of surfactants (Tween 80:sodium deoxycholate)
(X3) as three prime selected independent variables, which were
varied at two levels, low level (1) and high level (+1). The
values of two coded levels of three factors were assumed after
preliminary trials and are shown in Table 1. The in vitro per-
meation ﬂux (lg/cm2/h) of formulated transferosomal gels
containing insulin through goat ear skin was measured as
dependent variable. Design-Expert DX 8 Software was used
for the generation and evaluation of the statistical experimen-
tal design. The matrix of the design including response
obtained as the permeation ﬂux (lg/cm2/h) is shown in
Table 2.
2.4. Determination of drug entrapment efﬁciency
Transferosomal suspensions (total mount) were ultracentri-
fuged at 20,000 rpm and 10 C for 30 min. After centrifuga-
tion, 1 ml of supernatant was diluted with the addition of
9 ml phosphate saline buffer (pH 7.4) and then the absorbance
was measured using UV–Vis spectrophotometer (ThermoSpectronic UV-1, USA) by measuring absorbance at 214 nm.
The drug entrapment efﬁciency was calculated as below,
DEE ¼ ðWT WFÞ=WT  100% ð1Þ
where, DEE is the drug entrapment efﬁciency, WT is the total
amount of insulin in transferosomal suspensions: WF is the
free amount of insulin that was found in the supernatants.
2.5. Preparation of skin for in vitro skin permeation study
All the permeation experiments were done using porcine ear
skin, obtained from the slaughterhouse after sacriﬁcing the
animal within 1 h and prepared according to the literature
(Malakar et al., 2011). Then the hair was removed from the
upper portion of skin surface using an animal hair clipper
and subsequently, full thickness of the skin was harvested.
The fatty layer, adhering to the dermis side was removed by
surgical scalpel. Finally, the skin was rinsed with deionized
water and packed in an aluminum foil. The skin samples were
stored at 20 C and used within a week.
2.6. In vitro skin permeation study by Franz diffusion cell
In vitro skin permeation studies were carried out using Franz
diffusion cell. The cell consists of two chambers, the donor
and the receptor compartments with a diffusion area of
1.43 cm2. The donor compartment was open at the top and
was exposed to atmosphere. The excised porcine ear skin
was mounted between the compartments of the diffusion cell
with stratum corneum facing the donor compartment and
clamped into position. Magnetic stirrer bars were added to
the receptor chambers and ﬁlled with the receptor phase.
Phosphate buffer saline (PBS), pH 7.4 was used as receptor
medium. The small concentration of sodium azide (0.0025%
358 J. Malakar et al.w/v) was added to prevent any microbial growth (Pillai and
Panchagnula, 2004). The entire setup was placed over mag-
netic stirrer and the temperature was maintained at
37 ± 0.5 C. The skin sections were initially left in the Franz
cells for 2 h in order to facilitate hydration of the skin samples.
After this period, 5 ml of the appropriate formulation was
applied onto the surface of the skin. The transferosomal gels
containing insulin of 2.24 mg were used for the in vitro skin
permeation study. 0.5 ml of medium was collected from the
receptor compartment at predetermined intervals over study
period and replaced with the same amount of fresh buffer.
The amount of permeated drug was measured using UV–Vis
spectrophotometer (Thermo Spectronic UV-1, USA) by mea-
suring absorbance at 214 nm.
2.7. Permeation data analysis
Amount of insulin from transferosomal gel was permeated
through goat skin and was plotted against the function of time.
The slope and intercept of the linear portion of plots were
derived by regression. The ﬂux (J, lg/cm2/h) was calculated
as the slope is divided by the skin surface area (Nayak et al.,
2010; Ratha Adhikari et al., 2010).
The data of in vitro insulin release from various transferos-
omal gels were evaluated kinetically using various mathemati-
cal models like zero-order, ﬁrst-order, Higuchi and
Koresmeyer–Peppas model equations.
Zero order Kinetics : F ¼ K0t;
where F represents the fraction of drug released in time t, and
K0 is the zero-order release constant.
First order Kinetics : lnð1 FÞ ¼ K1t;
where F represents the fraction of drug released in time t, and
K1 is the ﬁrst-order release constant.
Higuch Model : F ¼ KHt1=2;
where F represents the fraction of drug released in time t, and
KH is the Higuchi dissolution constant.
Koresmeyer Peppas Model : F ¼ Kptn;
where F represents the fraction of drug released in time t, and
Kp is the Koresmeyer–Peppas release rate constant and n is the
diffusion exponent.
2.8. Vesicle size and zeta potential determination
One millilitre of transferosomal suspension was diluted by
10 ml of double distilled water and then vesicle size and zeta
potential were determined by a laser scattering particle size
analyzer (MALVERN ZETASIZER, MAL500999).
2.9. Iontophoresis experiment
Iontophoresis was performed using silver/silver chloride elec-
trodes according to the literature (Pillai et al., 2003). Silver
chloride electrodes were prepared as follows. Two silver wires
(0.5 mm diameter) were connected to a 12 V battery source
and immersed in 0.1 M hydrochloric acid. A gray silver chlo-
ride layer was gradually coated on one of the silver wires after
24 h. The silver wire representing the anode was immersed in
the donor compartment; while, a silver chloride-coatedcathode was inserted into the receptor compartment. Both
electrodes were connected to a constant current circuit. A di-
rect current of 0.5 mA/cm2 was applied throughout the study
period. The iontophoresis by that system was cathodal. At pre-
determined time intervals, 1 ml of medium samples were with-
drawn from the receptor and replaced with same amount of
fresh buffer. The amount of permeated drug was measured
using UV–VIS spectrophotometer (Thermo Spectronic UV-1,
USA) by measuring absorbance at 214 nm.
2.10. In vivo study
In vivo studies were performed in alloxan-induced diabetic al-
bino rats of either sex (weighing 240–362 g). The acclimatized
rats were kept fasting for 24 h with water ad libitum. All exper-
iments were performed between 8 am and 12 pm to minimize
circadian inﬂuences. The experimental protocol was subjected
to the scrutiny of the Institutional Animal Ethical Committee
and was cleared before starting. The animals were handled as
per the guidelines of committee for the purpose of control and
supervision on experimental animals (CPCSEA), New Delhi.
Prior to any treatment, the blood glucose level of these rats
was measured using a glucometer (ACCU CHECK) by the tail
cut method. The rats were made diabetic by intraperitoneal
administration of freshly prepared alloxan solution at a dose
of 150 mg/kg dissolved in 2 mM citrate buffer (pH 3.0). After
one week, alloxanized rats with fasting blood glucose of
300 mg/dl or more were considered diabetic and were em-
ployed in the study. All animals were kept in a normal diet
and condition.
The optimized transferosomal gel containing 2.24 mg insu-
lin was applied on the dorsal surface of each test animals by
adhesive tape after the removal of hair using hair remover
and the blood glucose level was measured after 24 h by the
above stated method.
3. Results and discussion
The purpose of using a full 23 factorial experimental design
was to conduct a comprehensive study of the effect of the pro-
cess parameters like ratio of lipids (soya lecithin:cholesterol)
(X1), ratio of lipids and surfactants (X2), ratio of surfactants
(Tween 80:sodium deoxycholate) (X3) and their interactions
using a suitable statistical tool (Design-Expert DX 8 Soft-
ware) by applying one-way ANOVA at 0.05 levels. A mathe-
matical modeling was carried out by using Eq. (6) to obtain
a ﬁrst-order polynomial equation depending on signiﬁcant
inﬂuences among three factors (X1, X2 and X3) of the factorial
design model.
Y ¼ b0 þ b1X1 þ b2X2 þ b3X3 þ b4X1X2 þ b5X1X3 þ b6X2X3
where Y= the dependent variable, while b0 = the intercept,
b1, b2, b3, b4, b5, b6 and b7 = regression coefﬁcients; X1, X2
and X3 = main factors; X1X2, X2X3, and X1X3 = interactions
between main factors.
The values of the insulin permeation ﬂux (J, lg/cm2/h) data
in 23 factorial design (Table 2) were ﬁtted to a ﬁrst-order poly-
nomial model. From the ANOVA results (Table 3) of the
model relating permeation ﬂux (J, lg/cm2/h) as response, it
can be noticed that all the coefﬁcients of this model equation
had statistic signiﬁcance (p< 0.05) with the model F-value
of 274.14 and R2 value of 0.9994. The model equation became:
Table 3 Summary of ANOVA for the response parameters.
Source Sum of square d.f.a Mean square F value p-value Prob > F
Model 49.36 6 8.23 274.14 0.0462
X1 1.59 1 1.59 53.08 0.0868
X2 20.07 1 20.07 668.59 0.0246
X3 1.74 1 1.74 57.95 0.0832
X1X2 6.28 1 6.28 209.36 0.0439
X1X3 2.57 1 2.57 84.72 0.0689
X2X3 17.14 1 17.14 571.11 0.0266
X1, X2 and X3 = main factors; X1X2, X2X3, and X1X3 = interactions between main factors.
a d.f. = Degree of freedom.
Figure 2 Effect of ratio of lipids (soya lecithin: cholesterol) and
ratio of lipids and surfactants on insulin permeation ﬂux (lg/cm2/
h) presented by response surface plot (a), and contour plot (b).
Figure 3 Effect of ratio of lipids (soya lecithin: cholesterol) and
ratio of surfactants (Tween 80: sodium deoxycholate) on insulin
permeation ﬂux (lg/cm2/h) presented by response surface plot (a),
and contour plot (b).
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þ 0:19X1X3 þ 7:50X2X3
Model simpliﬁcation was carried out by eliminating non-sig-
niﬁcant terms (p> 0.05) in the polynomial equation resultingfrom the multiple regression analysis (Nayak et al., 2011),
giving:
Y ¼ 11:87 2:00X2  1:03X1X2 þ 7:50X2X3
The inﬂuences of main effects (factors) on responses (here,
permeation ﬂux) were further elucidated by response surface
methodology. Response surface methodology is a widely pro-
Figure 4 Effect of ratio of lipids and surfactants, ratio of
surfactants (Tween 80: sodium deoxycholate) on insulin perme-
ation ﬂux (lg/cm2/h) presented by response surface plot (a), and
contour plot (b).
360 J. Malakar et al.ﬁcient approach in the development and optimization of drug
delivery devices (Kim et al., 2007). The three-dimensional re-
sponse surface graphs (Figs. 2a,3a,4a) and corresponding
two-dimensional contour plots (Figs. 2b,3b,4b) were generated
by the Design-Expert DX 8 Software. The three-dimensional
response surface graph is very useful in learning about the
main and interaction effects of the independent variables
(factors), whereas two-dimensional contour plot gives a visual
representation of values of the response (Joshi et al., 2010).
The three-dimensional response surface graphs relating perme-
ation ﬂux (J, lg/cm2/h) as response (Figs. 1a–3a) depicted theTable 4 Values of factors for the formulation of optimized transfe
Formulation
codes
Ratio of lipids
(soyalecithin:cholesterol) (X1)
Ratio of lipids and
surfactants (X2)
R
(T
F 9 5:3 1:1 1:
a % Error = [Difference between predicted value and observed value/Pincrease in permeation ﬂux with the increasing of ratio of lipids
and surfactants (X2), mainly. The two-dimensional contour
plots relating to permeation ﬂux (J, lg/cm2/h) indicated non-
linear relationships between the ratio of lipids and surfactants
(X2) and other individual factors investigated in this study
(ratio of lipids, X1 and ratio of surfactants, X3) (Figs. 2b,4b).
However, almost linear relationship between and ratio of
lipids, (X1) and ratio of surfactants was presented by the other
two-dimensional contour plot (Fig. 3b) given by the software.
A numerical optimization technique using the desirable
approach was employed to develop the new formulation of de-
sired response (desired quality). The desirable ranges of the
independent variables (factors) were restricted to X1 = 6.34,
X2 = 1, and X3 = 1.50. The optimal value of response was ob-
tained by numerical analysis using the Design-Expert DX 8
Software. In order to evaluate the optimization capability of
model generated according to the results of the full 23 factorial
design, optimized transferosomal gel containing insulin was
prepared using the optimal process variable settings (Table
4) and the optimized gel was evaluated to determine the perme-
ation ﬂux (J, lg/cm2/h) through porcine ear skin. The in vitro
permeation ﬂux for the optimized gel was measured
13.50 ± 0.22 lg/cm2/h through porcine ear skin with small
error-value (6.80%). This reveals that mathematical models
obtained from the full 23 factorial design were well ﬁtted. Cevc
et al. reported that the transdermal permeation of drug was
usually 10 times greater than conventional vesicles, when the
deformable vesicles were applied topically (Cevc et al., 1998).
This is due to the inﬂuence of hydration force caused by the
difference in water concentration by deformable vesicles con-
taining the sodium deoxycholate. Furthermore, it has been
also reported that the membrane ripples were found after the
addition of deoxycholate to phospholipids vesicles. These
ripples further more serve as intermembrane attachment site
for membrane fusion (Schubert et al., 2000). All these transfer-
osomal suspensions showed drug entrapment efﬁciency of
56.55 ± 0.37 (F 9) to 60.23 ± 0.44% (F 4) (Table 5). The aver-
age vesicle diameter range of optimized transferosomal suspen-
sion was 625–815 nm (Fig. 5), whereas, zeta potential of that
transferosomal suspension was – 14.30 mV. The skin has also
slight negative charge. Therefore, the negative zeta potential of
the optimized transferosomal gel containing insulin might
cause little inﬂuence in improved drug permeation through
porcine skin due to electrostatic repulsion between the same
charge of the skin surface and the optimized gel.
We also studied the in vitro skin permeation of optimized
transferosomal gel containing insulin by iontophoresis with
0.5 mA/cm2 current supply for the further improvement of
insulin permeation and we found that in vitro permeation ﬂux
measured 17.60 ± 0.03 lg/cm2/h through porcine ear skin,rosomal gel containing insulin (F 9).
atio of surfactant
ween 80:Na deoxycholate) (X3)
Flux, J (lg/cm2/h)
Observed
(Mean ± SE, n= 3)
Predicted
3 13.50 ± 0.22 12.64
% Errora
6.80
redicted value] · 100.
Table 5 Drug entrapment efﬁciencies of various transferoso-
mal gels containing insulin.
Formulation
codes
Drug entrapment eﬃciency
(%) (Mean ± SE, n = 3)
F 1 59.77 ± 0.56
F 2 60.72 ± 0.48
F 3 62.05 ± 0.56
F 4 60.23 ± 0.44
F 5 62.08 ± 0.57
F 6 57.27 ± 0.31
F 7 60.95 ± 0.44
F 8 58.68 ± 0.48
F 9 56.55 ± 0.37
Figure 5 The vesicle size distribution curve of optimized
transferosomal suspension (F 9) (before incorporation into gel).
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phoresis. It is reported that 0.5 mA/cm2 of current supply
has produced maximum drug permeation through the layers
of the skin (Pillai and Panchagnula, 2004). Therefore, in this
iontophoresis experiment, we have used 0.5 mA/cm2 of current
supply. Iontophoresis is one of the important electrically based
transdermal drug permeation enhancement technique (Molok-
hia et al., 2008; Semalthy et al., 2007). Iontophoresis may beFigure 6 Cumulative amount of in vitro insulin permeated through p
gels (F 1–F 9). (Mean ± SE, n= 3).deﬁned as the facilitation of ionizable drug permeation across
the skin by an applied electrical potential, the driving force of
which may be simply occurred as electrostatic repulsion
(Kumar and Philip, 2007). This technique utilizes the applica-
tion of small electric current to a drug reservoir on the skin,
with the similarly charged electrodes (on the surface of the
skin) placed together in the drug reservoir producing a repul-
sion effect that effetely drives the drug molecules away from
the electrode and into the skin (Kumar and Philip, 2007).
Amount of insulin permeated through porcine skin over
24 h period was plotted against the function of time (Fig. 6)
and this result showed that the high permeation proﬁle of opti-
mized transferosomal gel containing insulin (F 9) over 24 h. A
comparative in vitro permeation proﬁle of optimized transfer-
osomal gel containing insulin (F 9) in normal condition and
iontophortic condition with the inﬂuence of current supply,
0.5 mA/ cm2 was presented in Fig. 7. The in vitro permeation
proﬁle of optimized transferosomal gel containing insulin by
iontophoresis showed higher permeation proﬁle than of in nor-
mal condition, which was coincided well with permeation ﬂux
data.
In order to predict and correlate the in vitro insulin perme-
ation behavior from these transferosomal gels through porcine
skin, it is necessary to ﬁt into a suitable mathematical model.
The in vitro drug permeation data from various transferosomal
gels containing insulin through porcine skin were evaluated
kinetically by various mathematical models like zero-order,
ﬁrst-order, Higuchi, and Korsmeyer-Peppas Model. The
results of the curve ﬁtting into these above mentioned mathe-
matical models indicate the in vitro insulin permeation behav-
ior of transferosomal gels (F 1–F 9) (Table 6). When respective
correlation coefﬁcients were compared, it was followed the
zero-order kinetics (R2 = 0.9232–0.9989) over a period of
24 h. This indicates that the in vitro insulin permeation behav-
ior from these transferosomal gels through porcine skin was in
controlled release manner throughout the in vitro insulin
permeation study.
The Korsmeyer-Peppas model was employed in the in vitro
insulin permeation behavior analysis of these formulations to
distinguish between two competing release mechanisms: a
Fickian (non-steady) diffusional release when n 6 0.5 and aorcine skin per unit area vs. time proﬁle of various transferosomal
Table 6 Results of curve ﬁtting of the in vitro skin permeation
data of various transferosomal gels (F 1–F 9)
R2 values
Formulation
codes
Zero
order
First
order
Higuchi
Model
Korsmeyer-
Peppas
Diﬀusional
exponent (n)
F 1 0.9232 0.6056 0.9340 0.9242 1.1855
F 2 0.9941 0.7915 0.8524 0.9973 0.9937
F 3 0.9941 0.8225 0.6798 0.9895 0.9827
F 4 0.9974 0.7614 0.7863 0.9901 0.9353
F 5 0.9982 0.7094 0.7224 0.9866 1.1723
F 6 0.9958 0.7606 0.7984 0.9978 0.9211
F 7 0.9969 0.8625 0.7928 0.9759 1.0992
F 8 0.9952 0.7574 0.7998 0.9926 0.9999
F 9 0.9971 0.7966 0.6812 0.9850 1.1496
Figure 8 In vivo blood glucose level (mg/dl) in alloxan-induced
diabetic rats. (Mean ± SE, n= 6) Negative control: Before
alloxanization; Positive control: After 3 days of alloxanization;
Test: After 24 h of transdermal administration of optimized
transferosomal gel containing insulin in alloxan induced diabetic
rats.
Figure 7 Cumulative amount of in vitro insulin permeated
through porcine skin per unit area vs. time proﬁle of optimized
transferosomal gel (F 9) in normal condition and inontophoretic
condition with the inﬂuence of current supply, 0.5 mA/cm2.
(Mean ± SE, n= 3).
362 J. Malakar et al.case-II transport (zero-order) when nP 1. When the value of n
is between 0.5 and 1, this is indicative of non-Fickian, ‘anom-
alous’ release (Roberts et al., 1997). The determined values of
diffusion exponent (n) ranged between 0.9211 and 1.1855
(Table 6), indicating the drug release from these transferoso-
mal gels followed the case-II transport mechanism.
In vivo efﬁciencies of the optimized transferosomal gel con-
taining insulin were performed in Albino rats and estimated by
measuring the blood glucose level. The blood glucose level of
rats before the study, in alloxan-induced diabetic Albino rats
after 1 week of alloxanization, and after 24 h of transdermal
application of optimized transferosomal gel containing2.24 mg of insulin were measured as negative control, positive
control and test, respectively (Fig. 8). The in vivo result showed
that the measured blood glucose level for test was higher than
that of negative control; whereas test and negative control
were lower than that of positive control (before application
of test gel in alloxan-induced diabetic rats). These results sug-
gested that the tested transferosomal gel containing insulin
could be able to reduce the increased blood glucose level
through the transdermal route.
4. Conclusion
For large peptide like insulin, it is very difﬁcult to improve the
transport efﬁciency by increasing the concentrations of the
peptide due to the limitation in terms of cost and physical
stability. The major problems of conventional insulin therapies
possess several drawbacks like lower stability to different pH
and enzymatic system. However, the tranferosomal (highly
deformable vesicles) drug delivery system may be a better alter-
native for the conventional insulin therapy. The optimizzed
transferosomal gel containing insulin was obtained based on
23 factorial design, which showed the good permeation result
with in vitro permeation ﬂux of 13.50 ± 0.22 lg/cm2/h through
porcine ear skin. The iontophoretic inﬂuence on in vitro skin
permeation of optimized transferosomal gel also provided fur-
ther improvement of skin permeation ﬂux of 17.60 ± 0.03 lg/
cm2/h. The in vivo study of optimized transferosomal gel has
demonstrated prolonged hypoglycemic effect in alloxan-in-
duced diabetic rats over 24 h after transdermal administration.
The developed and optimized transferosomal gel containing
insulin can be transdermally administered in the treatment of
insulin dependent diabetes mellitus with maintaining lower
blood glucose level and improved patient compliance.
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